Fullmektig i Norge:
Org.nummer: 979993269
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2017.09.21, US 201762561629 P
2017.09.28, US 201762564951 P
"Developing Solid Oral Dosage Forms : Pharmaceutical Theory and Practice", 2 January 2008, PROQUEST, article NANCY SEVER: "Process Analytical Technology in Solid Dosage Development and Manufacturing", XP055565050 (B1)
"Pharmaceutical Process Scale-Up", 2 January 2011, PROQUEST, article JAMES K PRESCOTT: "Powder handling", XP055565041 (B1)
WO-A2-2016/210180 (B1)
UNKNOWN: "INGREZZA - FDA approved Label", 1 April 2017 (2017-04-01), pages 1 - 16, XP055530608, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209241lbl.pdf> [retrieved on 20181205] (B1)
"Pharmazeutische Technologie", 2 January 2000, article FAHR: "Kapseln", pages: 237, XP055565406 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende, AR676518027
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Beskrivelse / Fakturanummer Frist Beløp Status |
---|
300364860
expand_more
expand_less
7150
Fakturert
Valideringsgebyr EP-patent
7150 = 1 X 7150
|